News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
News
Drug Development
Evotec AG Announces Phase I Initiation With P2X7 Antagonist
October 9, 2008
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
HAMBURG, Germany, Oct. 9, 2008 (GLOBE NEWSWIRE) -- Evotec AG (Nasdaq:EVTC) (Frankfurt:EVT) announced today that Phase I clinical studies for its proprietary, small molecule P2X7 receptor antagonist have been initiated.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase I
Europe
MORE ON THIS TOPIC
ALS
ALS Community Petitions FDA To Reconsider BrainStorm’s NurOwn, Pointing to Recent Survival Data
July 8, 2025
·
3 min read
·
Heather McKenzie
Immunology and inflammation
Jasper Crashes as Compromised Drug Lot Confounds Urticaria Study
July 8, 2025
·
2 min read
·
Tristan Manalac
Immunology and inflammation
Cogent Jumps on Positive Mid-Stage Mastocytosis Data and NDA Plans
July 7, 2025
·
1 min read
·
Dan Samorodnitsky
Drug Development
5 Second-Half Biopharma Milestones To Watch
July 7, 2025
·
8 min read
·
Tristan Manalac
